放射性碘治疗Graves甲亢后生活质量较抗甲状腺药物或手术更差:长期随访
该研究评估1186例Graves病患者治疗6-10年后的生活质量,发现无论何种治疗方式,患者甲状腺相关生活质量均差于一般人群。放射性碘治疗者在多数量表上的甲状腺相关和总体生活质量差于抗甲状腺药物或手术者。
要点
- Graves病患者治疗6-10年后生活质量仍低于一般人群。
- 放射性碘治疗者甲状腺相关及总体生活质量多数量表差于药物或手术。
- 需进一步研究证实放射性碘对生活质量的负面影响。
核心结论
- Graves病治疗后6-10年生活质量仍低于一般人群,放射性碘治疗者多数量表评分更差。
研究设计与样本
- 基于2003-2005年发病率研究的亚队列,纳入1186例Graves病患者,975例返回ThyPRO问卷,964例返回SF-36问卷。
主要发现
- 无论治疗方式,Graves病患者甲状腺相关生活质量均差于一般人群(n=712)。
- 放射性碘治疗者在多数ThyPRO和SF-36量表上评分差于抗甲状腺药物或手术者。
- 敏感性分析支持放射性碘对生活质量相对负面影响的结论。
临床怎么用
- 选择Graves病治疗方案时需考虑放射性碘可能对长期生活质量的不利影响。
局限性
- 非随机队列,与丹麦常模数据比较,患者年龄偏大,放射性碘组可能病程更长,缺乏评估时甲状腺功能信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperthyroidism is known to have a significant impact on quality of life (QoL), at least in the short term. The purpose of the present study was to assess QoL in patients 6-10 years after treatment for Graves' disease (GD) with radioiodine (RAI) compared to those treated with thyroidectomy or antithyroid drugs (ATD) as assessed with both thyroid-specific Thyroid-Related Patient-Reported Outcome (ThyPRO) questionnaire and general (36-item Short Form Health Status) QoL survey. METHODS: The study evaluated 1186 GD patients in a sub-cohort from an incidence study 2003-2005 who had been treated according to routine clinical practice at seven participating centers. Patients were included if they had returned the ThyPRO (n = 975) and/or the 36-item Short Form Health Status survey questionnaire (n = 964) and informed consent at follow-up. Scores from ThyPRO were compared to scores from a general population sample (n = 712) using multiple linear regression adjusting for age and sex as well as multiple testing. Treatment-related QoL outcome for ATD, RAI, and surgery were compared, including adjustment for the number of treatments received, sex, age, and comorbidity. RESULTS: Regardless of treatment modality, patients with GD had worse thyroid-related QoL 6-10 years after diagnosis compared to the general population. Patients treated with RAI had worse thyroid-related and general QoL than patients treated with ATD or thyroidectomy on the majority of QoL scales. Sensitivity analyses supported the relative negative comparative effects of RAI treatment on QoL in patients with hyperthyroidism. CONCLUSIONS: GD is associated with a lower QoL many years after treatment compared to the general population. In a previous small randomized controlled trial, no difference was found in patient satisfaction years after ATD, RAI, or surgery. Now, it is reported that in a large non-randomized cohort, patients who received RAI had adverse scores on ThyPRO and 36-item Short Form Health Status survey. These findings in a Swedish population are limited by comparison to normative data from Denmark, older age, and possibly a more prolonged course in those patients who received RAI, and a lack of information regarding thyroid status at the time of evaluation. The way RAI may adversely affect QoL is unknown, but since the results may be important for future considerations regarding treatment options for GD, they need to be substantiated in further studies.
引用
- Törring O, Watt T, Sjölin G, et al. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey. Thyroid. 2019. PMID: 30667296. doi:10.1089/thy.2018.0315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。